Keywords: Tranzyme, Options, Sale or merger; Ache, Brazil, Bidding interest

Tranzyme exploring options, including sale of the firm; is Ache up for sale?

Article | 11 February 2013

Print This

Following two recent R&D pipeline disappointments, the board of directors of US biotech firm Tranzyme (Nasdaq: TZYM) has ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in